XERS biotech catalysts & pipeline

XERIS BIOPHARMA HOLDINGS INC · Data as of 2026-10-25

Upcoming catalysts

levothyroxine — Topline data

in late 2028

expected initiation of Cornerstone by year-end 2026, the expected initiation of Touchstone in 2027 and completion of Touchstone in time for inclusion in the Company's NDA submission, and the expected timing of topline results in late 2028;

Source filing

levothyroxine — PDUFA

in 2030

the timing and likelihood of regulatory approval and commercialization of XP-8121, including potential FDA approval and commercial launch in 2030;

Source filing

levothyroxine — Regulatory decision

2030

Cornerstone trial expected to initiate by year-end, fully aligned with FDA feedback on endpoints and statistical power; data expected late 2028, approval and launch anticipated in 2030

Source filing

levothyroxine — Conference presentation

Nov 6

Presentation : Friday, November 6, 2026, 10:00 a.m. EST

Source filing

Explore the free biotech catalyst calendar